Should pharmaceutical companies invest in MDM services and software?

What do you estimate that large and mid-tier pharmaceutical companies will spend on master data management (MDM) services and software from 2010 to 2012?

    Requires Free Membership to View

The money that pharma companies stand to save as a result of MDM will more than exceed their investments as long as they:

1. Deliberately plan their MDM programs. Successful MDM programs in pharma and health sciences mandate a requirements-driven, roadmap-enabled approach. This will also help with budgeting and resourcing -- ongoing challenges in many of these companies.

2. Apply rigor around their MDM investments. Pharma companies have a tendency to prefer vendors that are already in-house. We find that often translates into overinvestment.

This was first published in May 2010

There are Comments. Add yours.

TIP: Want to include a code block in your comment? Use <pre> or <code> tags around the desired text. Ex: <code>insert code</code>

REGISTER or login:

Forgot Password?
By submitting you agree to receive email from TechTarget and its partners. If you reside outside of the United States, you consent to having your personal data transferred to and processed in the United States. Privacy
Sort by: OldestNewest

Forgot Password?

No problem! Submit your e-mail address below. We'll send you an email containing your password.

Your password has been sent to: